Organism ID | Organism Name | Taxonomy Level | Family | SuperKingdom | Isolation Part | Collection Location | Collection Time | Reference |
---|---|---|---|---|---|---|---|---|
NPO1797 | Homo sapiens | Species | Hominidae | Eukaryota | blood serum |
PMID[25518943] |
||
NPO1797 | Homo sapiens | Species | Hominidae | Eukaryota | urine |
PMID[15537072] |
||
NPO20338 | Mus musculus | Species | Muridae | Eukaryota |
PMID[19425150] |
Target ID | Target Type | Target Name | Target Organism | Activity Type | Activity Relation | Value | Unit | Reference |
---|---|---|---|---|---|---|---|---|
NPT2 | Others | Unspecified | IC50 | = | 70000 | nM | 20004571 | |
NPT2 | Others | Unspecified | IC50 | = | 67000 | nM | 20004571 | |
NPT63 | Individual Protein | Bromodomain adjacent to zinc finger domain protein 2B | Homo sapiens | Potency | 707.9 | nM | PubChem BioAssay data set | |
NPT8 | Individual Protein | DNA polymerase iota | Homo sapiens | Potency | 112201.8 | nM | PubChem BioAssay data set | |
NPT2 | Others | Unspecified | Potency | 8196.1 | nM | PubChem BioAssay data set | ||
NPT2 | Others | Unspecified | Potency | 4466.8 | nM | PubChem BioAssay data set | ||
NPT11 | Individual Protein | Guanine nucleotide-binding protein G(s), subunit alpha | Homo sapiens | Potency | 25118.9 | nM | PubChem BioAssay data set |
Similarity level is defined by Tanimoto coefficient (Tc) between two molecules. Tc lies between [0, 1] where '1' indicates the highest similarity. What is Tanimoto coefficient
●  The left chart: Distribution of similarity level between NPC303899 and all remaining natural products in the NPASS database.
●  The right table: Most similar natural products (Tc>=0.56 or Top200).
Similarity Score | Similarity Level | Natural Product ID |
---|---|---|
0.9434 | High Similarity | NPC256849 |
0.9238 | High Similarity | NPC75131 |
0.9009 | High Similarity | NPC158847 |
0.8947 | High Similarity | NPC109322 |
0.8889 | High Similarity | NPC47936 |
0.887 | High Similarity | NPC180493 |
0.8596 | High Similarity | NPC252603 |
0.8319 | Intermediate Similarity | NPC199790 |
0.8246 | Intermediate Similarity | NPC148385 |
0.8241 | Intermediate Similarity | NPC476561 |
0.8103 | Intermediate Similarity | NPC278549 |
0.7768 | Intermediate Similarity | NPC476562 |
0.7368 | Intermediate Similarity | NPC167285 |
0.7368 | Intermediate Similarity | NPC76544 |
0.7368 | Intermediate Similarity | NPC10466 |
0.7368 | Intermediate Similarity | NPC226184 |
0.7304 | Intermediate Similarity | NPC476099 |
0.7155 | Intermediate Similarity | NPC476564 |
0.7094 | Intermediate Similarity | NPC119133 |
0.7042 | Intermediate Similarity | NPC321052 |
0.648 | Remote Similarity | NPC41958 |
0.6471 | Remote Similarity | NPC174114 |
0.6471 | Remote Similarity | NPC87981 |
0.6462 | Remote Similarity | NPC139776 |
0.6444 | Remote Similarity | NPC246193 |
0.6327 | Remote Similarity | NPC326694 |
0.632 | Remote Similarity | NPC4837 |
0.632 | Remote Similarity | NPC312187 |
0.6316 | Remote Similarity | NPC248007 |
0.6204 | Remote Similarity | NPC104011 |
0.592 | Remote Similarity | NPC18335 |
0.587 | Remote Similarity | NPC144223 |
0.5854 | Remote Similarity | NPC293163 |
0.584 | Remote Similarity | NPC59314 |
0.5822 | Remote Similarity | NPC317821 |
0.5821 | Remote Similarity | NPC327579 |
0.582 | Remote Similarity | NPC320256 |
0.5793 | Remote Similarity | NPC33996 |
0.5775 | Remote Similarity | NPC57279 |
0.5764 | Remote Similarity | NPC320818 |
0.576 | Remote Similarity | NPC273327 |
0.5753 | Remote Similarity | NPC129756 |
0.5745 | Remote Similarity | NPC287876 |
0.5714 | Remote Similarity | NPC161659 |
0.5714 | Remote Similarity | NPC209525 |
0.5674 | Remote Similarity | NPC14330 |
0.5638 | Remote Similarity | NPC229974 |
0.5638 | Remote Similarity | NPC314152 |
0.5629 | Remote Similarity | NPC164665 |
0.5629 | Remote Similarity | NPC189068 |
Similarity level is defined by Tanimoto coefficient (Tc) between two molecules.
●  The left chart: Distribution of similarity level between NPC303899 and all drugs/candidates.
●  The right table: Most similar clinical/approved drugs (Tc>=0.56 or Top200).
Similarity Score | Similarity Level | Drug ID | Developmental Stage |
---|---|---|---|
0.9434 | High Similarity | NPD9359 | Approved |
0.9434 | High Similarity | NPD9358 | Approved |
0.8929 | High Similarity | NPD580 | Discontinued |
0.887 | High Similarity | NPD9544 | Approved |
0.887 | High Similarity | NPD78 | Approved |
0.8793 | High Similarity | NPD281 | Approved |
0.8772 | High Similarity | NPD2221 | Clinical (unspecified phase) |
0.8696 | High Similarity | NPD4262 | Discontinued |
0.8644 | High Similarity | NPD1128 | Approved |
0.8644 | High Similarity | NPD1127 | Approved |
0.8596 | High Similarity | NPD9288 | Approved |
0.8596 | High Similarity | NPD9292 | Approved |
0.8596 | High Similarity | NPD76 | Approved |
0.8596 | High Similarity | NPD9289 | Approved |
0.8509 | High Similarity | NPD578 | Discontinued |
0.843 | Intermediate Similarity | NPD282 | Approved |
0.8403 | Intermediate Similarity | NPD1775 | Approved |
0.8403 | Intermediate Similarity | NPD1085 | Approved |
0.839 | Intermediate Similarity | NPD579 | Clinical (unspecified phase) |
0.8246 | Intermediate Similarity | NPD9086 | Approved |
0.8226 | Intermediate Similarity | NPD1119 | Phase 2 |
0.8051 | Intermediate Similarity | NPD9290 | Approved |
0.7874 | Intermediate Similarity | NPD535 | Approved |
0.7846 | Intermediate Similarity | NPD2253 | Discontinued |
0.7652 | Intermediate Similarity | NPD1117 | Clinical (unspecified phase) |
0.7634 | Intermediate Similarity | NPD1118 | Discontinued |
0.7586 | Intermediate Similarity | NPD8954 | Approved |
0.7586 | Intermediate Similarity | NPD8955 | Approved |
0.7556 | Intermediate Similarity | NPD7531 | Clinical (unspecified phase) |
0.7259 | Intermediate Similarity | NPD2179 | Discontinued |
0.7094 | Intermediate Similarity | NPD9291 | Approved |
0.7 | Intermediate Similarity | NPD4182 | Phase 3 |
0.7 | Intermediate Similarity | NPD4183 | Phase 3 |
0.6757 | Remote Similarity | NPD5321 | Phase 3 |
0.6484 | Remote Similarity | NPD9360 | Approved |
0.6415 | Remote Similarity | NPD4155 | Approved |
0.6389 | Remote Similarity | NPD1730 | Discontinued |
0.6357 | Remote Similarity | NPD237 | Clinical (unspecified phase) |
0.6316 | Remote Similarity | NPD9084 | Phase 2 |
0.625 | Remote Similarity | NPD757 | Phase 3 |
0.6211 | Remote Similarity | NPD3041 | Approved |
0.6179 | Remote Similarity | NPD9626 | Clinical (unspecified phase) |
0.6148 | Remote Similarity | NPD9408 | Phase 3 |
0.6131 | Remote Similarity | NPD9633 | Phase 3 |
0.6125 | Remote Similarity | NPD3081 | Clinical (unspecified phase) |
0.6094 | Remote Similarity | NPD9373 | Approved |
0.6058 | Remote Similarity | NPD870 | Clinical (unspecified phase) |
0.6026 | Remote Similarity | NPD9605 | Phase 3 |
0.6 | Remote Similarity | NPD9374 | Approved |
0.5971 | Remote Similarity | NPD248 | Discontinued |
0.592 | Remote Similarity | NPD8836 | Approved |
0.5894 | Remote Similarity | NPD3708 | Phase 2 |
0.5891 | Remote Similarity | NPD9375 | Discontinued |
0.5865 | Remote Similarity | NPD9606 | Approved |
0.584 | Remote Similarity | NPD8837 | Clinical (unspecified phase) |
0.5821 | Remote Similarity | NPD9607 | Approved |
0.5821 | Remote Similarity | NPD307 | Approved |
0.5811 | Remote Similarity | NPD4240 | Approved |
0.5789 | Remote Similarity | NPD1250 | Clinical (unspecified phase) |
0.5778 | Remote Similarity | NPD9409 | Discontinued |
0.5764 | Remote Similarity | NPD1121 | Approved |
0.5764 | Remote Similarity | NPD1120 | Approved |
0.5745 | Remote Similarity | NPD8829 | Clinical (unspecified phase) |
0.5735 | Remote Similarity | NPD1790 | Clinical (unspecified phase) |
0.5714 | Remote Similarity | NPD193 | Suspended |
0.5714 | Remote Similarity | NPD3696 | Approved |
0.5714 | Remote Similarity | NPD3695 | Approved |
0.5685 | Remote Similarity | NPD1808 | Phase 1 |
0.5638 | Remote Similarity | NPD185 | Approved |
0.5625 | Remote Similarity | NPD9083 | Clinical (unspecified phase) |
0.5605 | Remote Similarity | NPD1017 | Clinical (unspecified phase) |
PubChem CID   | 79437 |
ChEMBL   | CHEMBL1767 |
ZINC   |
Molecular Weight:   | 210.08 |
ALogP:   | -0.8914 |
MLogP:   | 1.57 |
XLogP:   | -1.093 |
# Rotatable Bonds:   | 4 |
Polar Surface Area:   | 78.67 |
# H-Bond Aceptor:   | 6 |
# H-Bond Donor:   | 1 |
# Rings:   | 2 |
# Heavy Atoms:   | 15 |